C4 Therapeutics (NASDAQ:CCCC) Issues Earnings Results, Misses Estimates By $0.05 EPS

Posted by Jared Coughlin on Feb 28th, 2025

C4 Therapeutics (NASDAQ:CCCC – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.05), Zacks reports. The business had revenue of $5.18 million during the quarter, compared to the consensus estimate of $4.43 million. C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%.

C4 Therapeutics Stock Down 1.9 %

CCCC stock opened at $2.60 on Friday. C4 Therapeutics has a 52 week low of $2.59 and a 52 week high of $11.88. The firm has a market capitalization of $183.53 million, a P/E ratio of -1.53 and a beta of 2.95. The company has a fifty day simple moving average of $3.54 and a two-hundred day simple moving average of $4.83.

Analysts Set New Price Targets

Several equities analysts have recently commented on CCCC shares. Wells Fargo & Company raised shares of C4 Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $8.00 to $12.00 in a report on Thursday, December 19th. Stephens started coverage on shares of C4 Therapeutics in a report on Monday, November 18th. They set an “equal weight” rating and a $4.00 price objective for the company. Finally, UBS Group upgraded C4 Therapeutics to a “hold” rating in a research report on Friday, February 14th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.50.

View Our Latest Stock Analysis on C4 Therapeutics

About C4 Therapeutics

(Get Free Report)

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.